SAIL66

SAIL66 is a next-generation tri-specific monoclonal antibody designed as a T-cell engager (TCE) for the treatment of solid tumors expressing Claudin 6 (CLDN6). It binds to CLDN6 on tumor cells with one Fab arm and to both CD3 and CD137 on T cells with the other Fab arm. This dual engagement activates T cells through CD3 signaling and provides co-stimulation via CD137, resulting in enhanced antitumor activity compared to conventional CLDN6-targeting TCEs. Preclinical studies have shown that SAIL66 increases intratumoral T-cell infiltration, reduces exhausted T cell populations, and demonstrates high specificity for CLDN6 without binding to related claudin family members. Clinical trials are ongoing for ovarian cancer and other solid tumors expressing CLDN6.

Other names

anti-CLDN6/CD3/CD137 trispecific antibodyCLDN6 T-cell engagerCLDN-6 T-cell engagerCLDN 6 T-cell engageranti-CLDN6/CD3 bispecific antibody SAIL66